Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Congratulations to the PReSUTINeB study on hitting their recruitment target today! Thanks to the research team, the sites and all who have taken part.

This study is a randomised placebo-controlled study investigating whether an immunotherapy treatment can prevent symptomatic urinary tract infections (UTI) in patients with neurogenic bladder dysfunction. 48 participants across 2 two centres in the UK (Stoke Mandeville Hospital, Buckinghamshire and Oxford Centre for Enablement) have been recruited. The Investigators are also looking at the signs and symptoms experienced during a symptomatic UTI. Participants will be on the study treatment for 3 months and followed up for 3 months after that.

Similar stories

SCIENCE spreads across the world

Oxford Trauma are pleased to open their first overseas site for the SCIENCE study.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.

PRoCuRe opens to recruitment

The Partial Rotator Cuff Tear Repair Trial (PRoCuRe) is open to recruitment at Oxford University Hospitals NHS Foundation Trust after achieving OCTRU Green Light approval!

IMP-MEL Trial given Green Light to open

OCTRU have now given Green Light approval for IMP MEL to open. This is a phase 1 first-in-human dose finding/randomised phase 2 study of IMM60 and pembrolizumab in advanced melanoma and NSCLC.